Free Trial

Illumina (ILMN) Stock Forecast & Price Target

Illumina logo
$95.12 -4.19 (-4.22%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$96.44 +1.32 (+1.38%)
As of 09/12/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Illumina - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
2
Hold
11
Buy
6

Based on 19 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 2 have given a sell rating, 11 have given a hold rating, and 6 have given a buy rating for ILMN.

Consensus Price Target

$123.06
29.37% Upside
According to the 19 analysts' twelve-month price targets for Illumina, the average price target is $123.06. The highest price target for ILMN is $200.00, while the lowest price target for ILMN is $80.00. The average price target represents a forecasted upside of 29.37% from the current price of $95.12.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ILMN Analyst Ratings Over Time

TypeCurrent Forecast
9/14/24 to 9/14/25
1 Month Ago
8/15/24 to 8/15/25
3 Months Ago
6/16/24 to 6/16/25
1 Year Ago
9/15/23 to 9/14/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
12 Buy rating(s)
Hold
11 Hold rating(s)
11 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$123.06$124.58$126.94$151.05
Forecasted Upside29.37% Upside24.44% Upside40.66% Upside16.93% Upside
Consensus RatingHoldHoldHoldModerate Buy

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Illumina Stock vs. The Competition

TypeIlluminaMedical CompaniesS&P 500
Consensus Rating Score
2.21
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside29.37% Upside17,489.59% Upside10.72% Upside
News Sentiment Rating
Positive News

See Recent ILMN News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/2/2025Royal Bank Of Canada
3 of 5 stars
Conor McNamara
Conor McNamara
Not Rated
Set Target$124.00+26.76%
8/12/2025Daiwa America
5 of 5 stars
 DowngradeStrong-BuyHold
8/12/2025Daiwa Capital Markets
2 of 5 stars
 DowngradeOutperformNeutral$94.00-0.82%
8/4/2025Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set TargetOverweight$110.00+12.52%
8/4/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$100.00 ➝ $105.00+8.45%
8/1/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetHold$99.00 ➝ $105.00+9.19%
8/1/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetUnderweight$85.00 ➝ $90.00-7.83%
7/28/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$84.00 ➝ $105.00-3.93%
7/11/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSector OutperformSector Perform$125.00+24.94%
7/9/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHoldStrong Sell$85.00 ➝ $80.00-19.41%
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$116.00 ➝ $128.00+31.76%
5/15/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$190.00 ➝ $185.00+129.39%
5/9/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$120.00 ➝ $85.00+12.20%
5/9/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$122.00 ➝ $114.00+48.17%
2/28/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
2/28/2025HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold$100.00+12.40%
2/7/2025TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$177.00 ➝ $140.00+14.01%
11/5/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetNeutral$133.00 ➝ $145.00-4.89%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$160.00 ➝ $200.00+38.91%
8/28/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$150.00+14.59%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageHold$115.00+10.28%
3/20/2024OTR Global
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated Rating
12/15/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeUnderperformMarket Perform
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOutperform$175.00+48.76%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeNeutralUnderperform$140.00 ➝ $100.00-14.99%
10/12/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy$200.00+49.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:29 AM ET.


Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 12, 2025. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • The current stock price is around $98.93, showing a recent increase of 1.3%, which may indicate positive market sentiment.
  • Illumina, Inc. reported earnings per share of $1.19, surpassing analysts' expectations, which reflects strong financial performance.
  • The company has a robust return on equity of 28.93%, suggesting effective management and profitability in generating returns for shareholders.
  • With a market capitalization of approximately $15.21 billion, Illumina, Inc. is positioned as a significant player in the life sciences sector, attracting institutional investors.
  • Illumina, Inc. has set a positive earnings guidance for FY 2025, indicating potential growth and stability in future earnings.

Illumina
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • The company's revenue has declined by 4.8% year-over-year, which may raise concerns about its growth trajectory.
  • Analysts have mixed ratings on the stock, with a consensus rating of "Hold," indicating uncertainty about its future performance.
  • Illumina, Inc. has a debt-to-equity ratio of 0.66, which, while manageable, suggests that the company is using some leverage that could pose risks in a downturn.
  • Recent price targets from analysts vary significantly, with some suggesting a lower target, which may indicate differing views on the company's valuation.
  • Market volatility, as indicated by a beta of 1.43, suggests that the stock may experience larger price swings compared to the overall market, which could be a risk for investors.

ILMN Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $123.06, with a high forecast of $200.00 and a low forecast of $80.00.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 2 sell ratings, 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.

According to analysts, Illumina's stock has a predicted upside of 29.37% based on their 12-month stock forecasts.

Over the previous 90 days, Illumina's stock had 4 downgrades by analysts.

Analysts like Illumina less than other "medical" companies. The consensus rating for Illumina is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ILMN compares to other companies.


This page (NASDAQ:ILMN) was last updated on 9/14/2025 by MarketBeat.com Staff
From Our Partners